SCHEDULE: Vanguard Discloses 5.26% Stake in Haemonetics

Vanguard Capital Management has reported beneficial ownership of 5.26% of Haemonetics Corp. common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, has disclosed a beneficial ownership stake of 5.26% in Haemonetics Corp.
• The total number of shares beneficially owned is 2,445,817.
• Vanguard Capital Management holds sole voting power over 355,428 shares and sole dispositive power over 2,445,817 shares.
• This filing reflects securities held by Vanguard funds and other managed accounts where Vanguard exercises dispositive and/or voting power.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as a major institutional investor like Vanguard increasing or maintaining a significant stake often reflects confidence in the company's stability and future performance.

Positives

• Vanguard's investment indicates confidence in Haemonetics Corp. from a major institutional investor.
• The disclosure of a significant stake (5.26%) suggests potential for continued institutional support.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures inherent in a Schedule 13G filing.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain specific forward-looking statements or guidance from Haemonetics Corp.

Industry Context

StockSavvy.ai notes that Vanguard's acquisition of a significant stake in Haemonetics Corp. aligns with broader trends of institutional investors increasing their positions in healthcare technology companies with strong market positions and recurring revenue models.

Stakeholder Impact

• Shareholders may view Vanguard's increased stake as a positive endorsement, potentially leading to increased investor confidence and share price stability.
• The filing does not directly impact employees, customers, suppliers, or creditors, but sustained institutional interest can indirectly support the company's operational stability.

Key Dates

Recommendation

This filing indicates a significant institutional investor's sustained interest, which is a positive sign for stability. However, it does not provide new operational or financial performance data for Haemonetics Corp. itself, making it a 'hold' recommendation based solely on this disclosure, pending further company-specific news.

Keywords

Haemonetics Corp, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing